HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists].

Abstract
Lung tissues are capable of forming a large amount of thromboxane (TX) A2. In addition to platelet aggregation and artery smooth muscle contraction, TXA2 induces potent contraction of the airway smooth muscles and airway hypersensitivity, suggesting that this arachidonate cyclooxygenase metabolite can contribute to a pathophysiological role for bronchial asthma as well as cardiovascular diseases. In this respect, many compounds competitively antagonizing TP (PGH2/TXA2) receptor, which is stimulated by not only TXA2 but also prostaglandin (PG) D2, PGF2 alpha, PGH2 and others, have been developed so far. Among these, several compounds have been proved or are being proved to be beneficial for treating of bronchial asthma in clinical. In this review, the efficacy of TP receptor blockers for bronchial asthma through the experimental results reported was discussed.
AuthorsS Kohno
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 54 Issue 2 Pg. 551-8 (Feb 1996) ISSN: 0047-1852 [Print] Japan
PMID8838113 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Receptors, Thromboxane
  • Thromboxane A2
Topics
  • Animals
  • Asthma (drug therapy)
  • Humans
  • Receptors, Thromboxane (antagonists & inhibitors)
  • Thromboxane A2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: